Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 4 1Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Sarcoma 1Polycythemia Vera 1Myeloproliferative Disorders 1Leukemia, Myeloid, Acute 1Leukemia 1Histiocytoma, Malignant Fibrous 1Carcinoma, Transitional Cell 1

Interventions

fludarabine phosphate 18Cyclophosphamide 16Peripheral Blood Stem Cell Transplantation 12Whole-Body Irradiation 11Busulfan 11Tacrolimus 10Mycophenolic Acid 10ruxolitinib 9fludarabine 7Methotrexate 6Cyclosporine 6Radiotherapy 5Aspirin 5Prednisone 4Melphalan 4Imatinib Mesylate 4Biopsy 4Antilymphocyte Serum 4peginterferon alfa-2a 3givinostat hydrochloride 3givinostat 3Stem Cell Transplantation 3Specimen Handling 3Decitabine 3bomedemstat 2Thiotepa 2Surveys and Questionnaires 2N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 2Methylprednisolone 2Lenalidomide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Polycythemia Vera × Phlebotomy × Clear all
NCT04182100 2025-09-15

Efficacy and Safety of P1101 in Polycythemia Vera Patients for Whom the Standard of Treatment is Difficult to Apply

PharmaEssentia Japan K.K.

Phase 2 Completed
29 enrolled 15 charts
Myeloid

Myeloproliferative Disorders, Polycythemia Vera

Data powered by HemOnc (CC BY 4.0) Colophon âš¡